Jeremy Skillington

Jeremy Skillington, PhD
Co-Founder and Chief Executive Officer


Scientist turned Entrepreneur, Dr. Skillington gained his BSc (Hons) and Ph.D. in Biochemistry from NUI Galway, Ireland and performed Post-Doctoral research at the University of California, San Francisco. Leaving Academia to join the Biotech industry, Dr. Skillington spent over six and a half years in the Business Development group at global Biotech leader, Genentech, Inc, executing over 40 licensing, investment and collaboration transactions. Dr. Skillington returned to Ireland in 2009 to lead Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd. Dr Skillington Co-Founded TriMod Therapeutics and raised €750,000 ($1M) in Seed Capital financing for the company.

Kingston Mills

Prof Kingston Mills, PhD
Co-Founder


Prof Mills is a globally recognized and distinguished leader in the field of Immunology and brings over 30 years of academic (TCD, University College London, NUI Maynooth) and entrepreneurial (Co-Founder of Opsona Therapeutics) excellence to TriMod. Prof Mills has published ›170 peer-reviewed articles, is co-inventor on 14 patents and applications, is Director of the Immunology Research Centre at TCD and is a member of the Royal Irish Academy. Prof. Mills graduated from Trinity College, Dublin with a B.Sc. in Biochemistry and a Ph.D. in Immunology.

Bernd R. Seizinger

Bernd R. Seizinger, M.D., Ph.D
Director


Has been Executive Chairman of Opsona Therapeutics Ltd. since 2011 and Chairman of the Board of Directors since 2009. From 1998 to 2009, Dr. Seizinger was President & Chief Executive Officer of GPC Biotech (Munich, Germany; Princeton, NJ, USA; and Cambridge/Waltham, MA, USA) until GPC Biotech was merged into Agennix AG in 2009 (Dr. Seizinger is currently a Member of the Board of Directors of Agennix). From 1996 to 1998 Dr. Seizinger was EVP and CSO of Genome Therapeutics Corp. in Waltham/Boston, MA, USA. From 1992 to 1996, he was VP of Oncology Drug Discovery and VP of Corporate and Academic Alliances at Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ, USA.

Dr. Seizinger was on faculty at Massachusetts General Hospital and Harvard Medical School in Boston, MA, USA (1984-1992). Dr. Seizinger also held a visiting faculty position at the Department of Molecular Biology at Princeton University. He was awarded his M.D. from the Ludwig-Maximilians-University and his Ph.D. (summa cum laude) from the Max Planck Institute of Psychiatry both of which are located in Munich, Germany. He is the recipient of a number of scientific awards and has authored over one hundred publications.

John G. Armstrong

Professor John G. Armstrong MD, F.R.C.P.I., D.A.B.R., F.F.R.R.C.S.I.
Director


Professor Armstrong, Consultant Radiation Oncologist is a Board Member and ex-chairman of the Irish Cancer Society. Professor Armstrong was trained at Memorial-Sloan Kettering Cancer Center, where he performed his residency and was also Chief resident and attending for five years. He directed the lung cancer radiation research programme at Memorial-Sloan Kettering Cancer Center, and coauthored the chapter on non-small cell lung cancer chapter in 4th edition of; "DeVita, Hellman, and Rosenberg, Cancer: Principles and Practice of Oncology," Lippincott.

Professor Armstrong is currently the Director of Research at St. Lukes Hospital. Professor Armstrong was a founding member and past chairman of the Irish Clinical Oncology Research Group and is the Principal Investigator for several clinical trials. He is Medical Director for UPMC Cancer Centres Ireland.

Professor Armstrong has published numerous articles and has lectured extensively in the field of radiation oncology. He has been instrumental in the rollout of new procedures involving high tech radiation therapy procedures such as Intensity Modulated Radiation Therapy and stereotactic radiosurgery.

Martin Scully

Martin Scully
Board Observer


Martin Scully is Chief Executive of Oyster Capital Partners, the private investment vehicle established by Bill McCabe.

Martin is responsible for managing a variety of asset classes, primarily private equity investments in the information technology and waste sectors. In this role he evaluates private equity investments and works closely with investee companies. He also co-ordinates follow-on funding rounds in such companies and deals with investment banks and venture capital groups on their behalf.

Prior to taking up this position with Oyster Capital Partners, Martin was a partner with Farrell Grant Sparks, for 12 years, where he had responsibility for the firm's tax department, before establishing a unit focusing on the firm's financial services to technology sector clients.